Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Acadia Pharmaceuticals, Inc.

To join this class action, please complete the following Investor Certification.

Acadia Pharmaceuticals, Inc. [NASDAQ; ACAD] Investor Certification

Company Name
Plaintiff Certifies That:
The following information is true and correct to the best of my knowledge, information and belief: 1. I have reviewed the Complaint in this action and authorize the filing of this Certification as an exhibit to the Complaint, or any substantively similar complaint or amended complaint to be filed in the future. I retain the law office of Federman & Sherwood, and any other counsel with whom Federman & Sherwood deems appropriate to associate with, to pursue this action on my behalf on a contingency fee basis. 2. If chosen, I am willing to serve as a representative party on behalf of the class (the “Class”), either individually or as part of a group on behalf of the Class as defined in the Complaint, including providing testimony at deposition or trial (if necessary). I am also willing to participate on an executive committee of shareholders.
3. I have made the following transaction(s) during the Class Period in
securities (which are the subject of this action) as follows:
# Shares Purchased Date Of Purchase Price Paid Per Share Class Of Stock (e.g. Common) If Sold, # Of Shares Sold Date Sold (If Sold) Per Share Selling Price
4. I did not purchase these securities at the direction of my attorney or in order to participate in a lawsuit under the Securities Act of 1933 or the Securities Exchange Act of 1934. 5. During the 3-year period preceding the date of this Certification, I have not sought to serve, nor have I served, as a representative to any party or on behalf of any class in any action arising under the Securities Act of 1933 or the Securities Exchange Act of 1934. 6. I will not accept any payment if chosen to serve as a representative party on behalf of the Class beyond my pro rata share of an award to the Class, or as otherwise ordered and approved by the Court, except for such reasonable costs and expenses directly relating to my service as a representative of the Class and as ordered and approved by the Court.
Signed under penalty of perjury, under the laws of the United States of America on:*
MM slash DD slash YYYY
Investor Signature*
Please type: /s/ Your Full Name (e.g. /s/ John Doe)
Print Name*
Type Full Name Here
*
Home Address City State Zip
Home Telephone Number
Cell Telephone Number
Email Address
Secondary Email Address (if any)
By clicking on the button below, I intend to sign and execute this agreement and retain Federman & Sherwood to proceed on Plaintiff’s behalf on a contingency basis.

Oklahoma City, OK (July 25, 2018) – On July 19, 2018, a securities class action lawsuit was filed in the United States District Court for the Southern District of California against Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is April 29, 2016 through July 9, 2018. More specifically, this litigation was filed because defendants made false and/or misleading statements and/or failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

On July 9, 2018, the Southern Investigative Reporting Foundation (“SIRF”) published a report entitled “Acadia Pharmaceuticals: This Is Not a Pharmaceuticals Company.” Therein, SIRF stated that “evidence is mounting that something is horribly wrong with Acadia’s sole drug, Nuplazid, an antipsychotic for Parkinson’s disease patients who experience episodic hallucinations and delusions” and that “Acadia has accomplished its growth in ways that have attracted intense regulatory scrutiny for other drug companies” including “dispensing wads of cash to doctors to incentivize prescription writing and downplaying mounting reports of patient deaths.” On this news, Acadia’s stock price fell $1.21 per share, to close at $16.63 per share.

Plaintiff seeks to recover damages on behalf of all Acadia Pharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, September 17, 2018 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact: Robin Hester at rkh@federmanlaw.com

News & Current Cases

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Acadia Pharmaceuticals, Inc.

Acadia Pharmaceuticals, Inc. [NASDAQ; ACAD] Investor Certification

Plaintiff Certifies That:

Categories

let’s connect

OKLAHOMA Office

TEXAS Office

# Shares Purchased	Date Of Purchase	Price Paid Per Share	Class Of Stock (e.g. Common)	If Sold, # Of Shares Sold	Date Sold (If Sold)	Per Share Selling Price